

CITATION REPORT

List of articles citing

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

DOI: 10.2337/dc16-1771
Diabetes Care, 2017, 40, 943-950.

Source: <https://exaly.com/paper-pdf/66646671/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
136	Insulin analogues in type 1 diabetes mellitus: getting better all the time. 2017 , 13, 385-399		94
135	Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. <i>Diabetes Care</i> , 2017 , 40, 951-957	14.6	75
134	Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1773-1780	6.7	8
133	Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas. 2017 , 37, 885-887		
132	Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3). <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1389-1396	6.7	31
131	Real-World Challenges of Controller Adaptation with the Artificial Pancreas. 2017 , 19, 552-554		
130	Pharmacological Properties of Faster-Acting Insulin Aspart. 2017 , 17, 101		17
129	POSTPRANDIAL DOSING OF BOLUS INSULIN IN PATIENTS WITH TYPE 1 DIABETES: A CROSS-SECTIONAL STUDY USING DATA FROM THE T1D EXCHANGE REGISTRY. 2017 , 23, 1201-1209		16
128	Targeting One-Hour Postmeal Glucose: Is It Time for a Paradigm Switch in Diabetes Management?. 2017 , 19, 493-497		10
127	Möglichkeiten und Grenzen der aktuellen Insulintherapie. 2017 , 11, 37-45		
126	Fiasp: a new faster-acting insulin aspart formulation for diabetes. 2017 , 28, 37-38		3
125	Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1615-1622	6.7	22
124	Möglichkeiten und Grenzen der aktuellen Insulintherapie. 2018 , 15, 55-63		
123	Treatment of cystic fibrosis-related diabetes. 2018 , 6, 167		1
122	Glycemic Management in Adults With Type 1 Diabetes. 2018 , 42 Suppl 1, S80-S87		14
121	Analysis of "Laboratory and Benchtop Performance of a Mealtime Insulin Delivery System". 2018 , 12, 828-830		
120	Type 1 Diabetes in Children and Adolescents. 2018 , 717-736		2

119	Dual-hormone artificial pancreas: benefits and limitations compared with single-hormone systems. 2018 , 35, 450-459		33
118	Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1148-1155	6.7	50
117	Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them?. 2018 , 12, 152-154		2
116	Comment on Russell-Jones et al. <i>Diabetes Care</i> 2017;40:943-950. Comment on Bowering et al. <i>Diabetes Care</i> 2017;40:951-957. <i>Diabetes Care</i> , 2018 , 41, e27-e28		14.6
115	Response to Comment on Russell-Jones et al. <i>Diabetes Care</i> 2017;40:943-950. Comment on Bowering et al. <i>Diabetes Care</i> 2017;40:951-957. <i>Diabetes Care</i> , 2018 , 41, e29-e30	14.6	1
114	Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart. 2018 , 9, 303-310		13
113	The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 245-256	6.7	52
112	Digitale Tools und strukturierte Prozesse verbessern Therapiequalität. 2018 , 12, 55-55		
111	Postprandiale Hyperglykämie ist gefährlich. 2018 , 12, 55-55		
110	Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2885-2893	6.7	31
109	Préparations insuliniques au cours de la dernière décennie.. <i>Medecine Des Maladies Metaboliques</i> , 2018 , 12, 113-127	0.1	5
108	Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians. 2018 , 42, 3-18		19
107	Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?. 2018 , 9, 157-166		4
106	Lessons for modern insulin development. 2018 , 35, 1320-1328		9
105	Paediatric type 1 diabetes 2018: Clinical and research insights. 2018 , 23, 198-202		1
104	Emerging Technologies for Diabetes Care. 2018 , 20, S278-S284		21
103	Intensive Glycemic Treatment During Type 1 Diabetes Pregnancy: A Story of (Mostly) Sweet Success!. <i>Diabetes Care</i> , 2018 , 41, 1563-1571	14.6	12
102	ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. 2018 , 19 Suppl 27, 115-135		94

101	The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective. 2018 , 9, 187-197		4
100	Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes. 2018 , 20, S224-S232		18
99	Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. 2019 , 58, 421-430		11
98	Insulin Pumps and Artificial Pancreas. 2019 , 245-258		0
97	Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations. 2019 , 3, 1942-1957		9
96	Timing of Insulin with Meals in the Hospital: a Systems Improvement Approach. 2019 , 19, 110		1
95	Short-term fully closed-loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2718-2722	6.7	8
94	Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin. <i>Diabetes Therapy</i> , 2019 , 10, 1793-1800		6
93	Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2039-2047	6.7	25
92	Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial. <i>Diabetes Care</i> , 2019 , 42, 1255-1262	14.6	20
91	Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective. 2019 , 43, 515-523		21
90	Peptide Drug Design for Diabetes and Related Metabolic Diseases. 2019 , 351-368		
89	[Diagnosis and insulin therapy of type 1 diabetes mellitus (Update 2019)]. 2019 , 131, 77-84		1
88	Patient Assessment in Clinical Pharmacy. 2019 ,		2
87	Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials. <i>Diabetes Therapy</i> , 2019 , 10, 1029-1041	3.6	2
86	Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide. 2019 , 36, 49		39
85	Role of ultrafast-acting insulin analogues in the management of diabetes. 2019 , 31, 537-548		4
84	Are newer insulins always the better option?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019 , 26, 77-83	4	1

83	Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis. <i>Diabetes Therapy</i> , 2019 , 10, 177-188	3.6	2
82	BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1066-1070	6.7	22
81	Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus. 2019 , 58, 639-649		8
80	Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes. 2019 , 36, 771-775		2
79	A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 961-967	6.7	34
78	Update on postprandial hyperglycaemia: the pathophysiology, prevalence, consequences and implications of treating diabetes. 2020 , 220, 57-68		1
77	Update on postprandial hyperglycemia: The pathophysiology, prevalence, consequences and implications of treating diabetes. 2020 , 220, 57-68		1
76	Simple Post-Processing of Continuous Glucose Monitoring Measurements Improves Endpoints in Clinical Trials. 2020 , 14, 1074-1078		2
75	Risk of major cardiovascular events, severe hypoglycaemia, and all-cause mortality for users of insulin degludec versus insulin glargine U100-A Danish cohort study. 2020 , 36, e3225		5
74	Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. 2020 , 59, 155-172		17
73	Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review. <i>Diabetes Therapy</i> , 2020 , 11, 387-409	3.6	20
72	New Insulin to Treat Pregestational Diabetes in Pregnancy. 2020 , 76-87		
71	Biosimilars and Novel Insulins. 2020 , 27, e52-e61		3
70	Treatment of type 1 diabetes complicated by problematic hypoglycemia. 2020 , 391-406		
69	Biosynthetic Human Insulin and Insulin Analogs. 2020 , 27, e42-e51		10
68	Aktuelle Therapien und Technologien in der Kinderdiabetologie. 2020 , 20, 12-22		
67	A Reproducibility Rule for Choosing the Number of Imputations When Reporting Clinical Trials. 2020 , 1-6		
66	9. Pharmacologic Approaches to Glycemic Treatment:.. <i>Diabetes Care</i> , 2020 , 43, S98-S110	14.6	573

65	Recent Advances in Insulin Therapy. 2020 , 22, 929-936		9
64	Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1799-1807	6.7	29
63	An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients. 2020 , 12,		18
62	Insulin Pumps. 2020 , 22, S17-S31		1
61	The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 743-754	6.7	28
60	A survey of physician experience and treatment satisfaction using fast-acting insulin aspart in people with type 1 or type 2 diabetes. 2020 , 132, 320-327		4
59	Fast-Acting Insulin Aspart Use with the MiniMed 670G System. 2021 , 23, 1-7		19
58	Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions. 2021 , 20, 155-169		1
57	Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 448-455	14.6	4
56	9. Pharmacologic Approaches to Glycemic Treatment:.. <i>Diabetes Care</i> , 2021 , 44, S111-S124	14.6	388
55	Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study. 2021 , 23, 286-292		7
54	Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring Within a Real-World Setting: The GoBolus Study. 2021 , 23, 203-212		9
53	Glycaemic efficacy and safety of mealtime faster-acting insulin aspart administered by injection as compared to insulin aspart in people with diabetes mellitus: A meta-analysis of randomized controlled trials. 2021 , 38, e14515		7
52	Drug Resistance in Diabetes. 2021 , 423-459		
51	Diabetes Mellitus. 2021 , 814-883		1
50	Interindividual Variability in the Pharmacodynamic and Pharmacokinetic Characteristics of Recombinant Human Insulin and Insulin Aspart. 2021 , 43, 594-601.e1		3
49	CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial. 2021 , 11, e045650		
48	Fast-acting insulin aspart - from insulin portraits to patient portraits. 2021 , 8-16		

47	Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus. 2021 , 9,		
46	Living with Insulin: The story of insulin from people with diabetes. 2021 , 176, 108857		4
45	Si l'ère des insulines semi-synthétiques et biosynthétiques nous fait connaître. <i>Medecine Des Maladies Metaboliques</i> , 2021 , 15, 3S32-3S52	0.1	0
44	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2395-2401	6.7	1
43	Diabetes Technology Meeting 2020. 2021 , 15, 916-960		1
42	Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes. <i>Clinical Diabetes</i> , 2021 , 39, 347-357	2.9	0
41	Glucose control using fast-acting insulin aspart in a real-world setting: A 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2716-2727	6.7	4
40	One hundred years of insulin therapy. 2021 , 17, 715-725		5
39	Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?. <i>Clinical Diabetes</i> , 2021 , 39, 415-423	2.9	2
38	A Century of Progress in Diabetes Care with Insulin: A History of Innovations and Foundation for the Future. 2021 , 45, 629-640		2
37	Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial. 2021 , 68, 429-440		
36	Advances in newer basal and bolus insulins: impact on type 1 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021 , 28, 1-7	4	3
35	Glucocorticoid chronotherapy: a mini-review. <i>Endocrinology&Metabolism International Journal</i> , 2018 , 6,	0	1
34	Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study. <i>Diabetes Therapy</i> , 2021 , 12, 3067-3077	3.6	0
33	The impact of "faster aspart" on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump. <i>Anales De Pediatria (English Edition)</i> , 2021 , 95, 321-329	0.4	
32	Faster Insulin Aspart - a new prandial insulin analogue. <i>Vnitřní Lekarství</i> , 2017 , 63, 697-702	0.3	
31	Developments in the Management of Type 1 and Type 2 Diabetes. <i>European Endocrinology</i> , 2018 , 14, 13-14	3.4	1
30	Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2018 , 23, 351-361	1.6	1

29	Thérapeutique des troubles glycémiés. 2019 , 141-252		
28	Diabetes Mellitus. 2019 , 157-170		
27	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. <i>Diabetes Mellitus</i> , 2020 , 23, 140-160	1.6	
26	Rasante Weiterentwicklung der Therapiemöglichkeiten. <i>Pädiatrie Kinder- Und Jugendmedizin Hautnah</i> , 2020 , 32, 46-53	0	
25	Contrôle de la glycémie post-prandiale : apport des nouvelles formulations d'insuline ultra-rapides. <i>Medecine Des Maladies Metaboliques</i> , 2020 , 14, 718-726	0.1	
24	[The impact of «faster aspart» on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump]. <i>Anales De Pédiatrie</i> , 2020 , 95, 321-321	0.2	
23	Insulin discovery: A pivotal point in medical history. <i>Metabolism: Clinical and Experimental</i> , 2021 , 127, 154941	12.7	1
22	Effect of ultra-rapid insulin aspart on glycemic control in children with type 1 diabetes: the experience of a Portuguese tertiary centre.. <i>Diabetology International</i> , 2022 , 1-7	2.3	
21	Glycemic control after switching to faster aspart in adults with type 1 diabetes.. <i>Journal of Endocrinological Investigation</i> , 2022 , 1	5.2	
20	9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.. <i>Diabetes Care</i> , 2022 , 45, S125-S143	14.6	64
19	Management of hyperglycemia in critical care. <i>Journal of Diabetology</i> , 2022 , 13, 33	0.8	
18	Can Faster Aspart be Used to Optimize Glycemic Control With Insulin Pump Therapy? From Expectations to Lessons Learned After a Year of Use in the United States. <i>Clinical Diabetes</i> ,	2.9	0
17	Rapid-Acting Insulin Analogues: Theory and Best Clinical Practice in Type 1 and Type 2 Diabetes.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	6.7	1
16	What is the value of faster acting prandial insulin? Focus on ultra rapid lispro.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	6.7	1
15	Short-acting Insulin Analogues. 2022 , 179-193		
14	The Effect of Two Different Insulin Formulations on Postprandial Hyperglycemia after High and Low Glycemic-Index Meal in Type 1 Diabetes. 2022 , 14, 3316		
13	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. 2022 ,		8
12	Efficacy and safety of ultra rapid lispro (URLi) versus Lispro in children and adolescents with type 1 diabetes: PRONTO-Peds.		0

- 11 Bolus Insulin calculation without meal information. A reinforcement learning approach. **2022**, 102436 ○
- 10 Comparative assessment of modern parameters of glycemic control in children with type 1 diabetes after switching to fast-acting insulin aspart using Flash Glucose Monitoring in real clinical practice. **2022**, 25, 458-467 ○
- 9 100 anys de la comercialització de la insulina. Una carrera aïm por terminar. **2022**, ○
- 8 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2023. **2023**, 46, S140-S157 11
- 7 The 2021-2022 position of Brazilian Diabetes Society on insulin therapy in type 1 diabetes: an evidence-based guideline to clinical practice. **2022**, 14, ○
- 6 Au-delà des insulines actuelles : des réalisations prometteuses et quelques déillusions. **2022**, ○
- 5 Dépistage des anomalies de la tolérance au glucose et du diabète de mucoviscidose. Position de la Société française de la mucoviscidose (SFM), de la Société francophone du diabète (SFD) et de la Société française d'Endocrinologie et diabétologie pédiatrique (SFEDP). **2023**, ○
- 4 Significant publications in diabetes pharmacotherapy and technology in 2020. ○
- 3 Significant publications in diabetes pharmacotherapy and technology in 2020. **2023**, 18, 131-142 ○
- 2 100 years of the commercialization of insulin: A race yet to end. **2023**, 160, 268-274 ○
- 1 Diagnostik und Therapie des Typ 1 Diabetes mellitus (Update 2023). **2023**, 135, 98-105 ○